A novel hPirh2 splicing variant without ubiquitin protein ligase activity interacts with p53 and is down-regulated in hepatocellular carcinoma

FEBS Letters

Volumn 584, Issue 13, 2010, Pages 2772-2778

  Wu, Gang ^a   Sun, Meiqian ^a   Zhang, Liping ^a   Zhou, Juan ^a   Wang, Yi ^b   Huo, Keke ^a  

^a FUDAN UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; P53; Pirh2; Splicing variant; Ubiquitin ligase

Indexed keywords

COMPLEMENTARY DNA; PROTEIN P53; PROTEIN PIRH2; RING FINGER PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME ACTIVITY; GENE DELETION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; RNA SPLICING; RNA TRANSLATION;

AMINO ACID SEQUENCE; BASE SEQUENCE; BLOTTING, NORTHERN; CARCINOMA, HEPATOCELLULAR; GLUTATHIONE TRANSFERASE; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIVER; LIVER NEOPLASMS; MOLECULAR SEQUENCE DATA; MUSCLE, SKELETAL; MYOCARDIUM; PANCREAS; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; SEQUENCE HOMOLOGY, AMINO ACID; TUMOR SUPPRESSOR PROTEIN P53; TWO-HYBRID SYSTEM TECHNIQUES; UBIQUITIN-PROTEIN LIGASES;

EID: 77953729076     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2010.04.075     Document Type: Article

References (21)

1. Sun Y. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol. Ther. 2003, 2:623-629.
2. Robinson P.A., Ardley H.C. Ubiquitin-protein ligases - novel therapeutic targets?. Curr. Protein Pept. Sci. 2004, 5:163-176.
3. Hoeller D., Hecker C.M., Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat. Rev. Cancer 2006, 6:776-788.
4. Bernassola F., Karin M., Ciechanover A., Melino G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 2008, 14:10-21.
5. Leng R.P., et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003, 112:779-791.
6. Beitel L.K., Elhaji Y.A., Lumbroso R., Wing S.S., Panet-Raymond V., Gottlieb B., Pinsky L., Trifiro M.A. Cloning and characterization of an androgen receptor N-terminal-interacting protein with ubiquitin-protein ligase activity. J. Mol. Endocrinol. 2002, 29:41-60.
7. Lorick K.L., Jensen J.P., Fang S., Ong A.M., Hatakeyama S., Weissman A.M. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc. Natl. Acad. Sci. USA 1999, 96:11364-11369.
8. Zhang L., Li J., Wang C., Ma Y., Huo K. A new human gene hNTKL-BP1 interacts with hPirh2. Biochem. Biophys. Res. Commun. 2005, 330:293-297.
9. Logan I.R., Sapountzi V., Gaughan L., Neal D.E., Robson C.N. Control of human PIRH2 protein stability: involvement of TIP60 and the proteosome. J. Biol. Chem. 2004, 279:11696-11704.
10. Logan I.R., Gaughan L., McCracken S.R., Sapountzi V., Leung H.Y., Robson C.N. Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol. Cell. Biol. 2006, 26:6502-6510.
11. Corcoran C.A., Montalbano J., Sun H., He Q., Huang Y., Sheikh M.S. Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domains. J. Biol. Chem. 2009, 284:21955-21970.
12. Shi J., Huang Y., Sheikh M.S. Identification of Pirh2D, an additional novel isoform of Pirh2 ubiquitin ligase. Mol. Cell Pharmacol. 2010, 2:21-23.
13. Venables J.P. Aberrant and alternative splicing in cancer. Cancer Res. 2004, 64:7647-7654.
14. Wang Z., Lo H.S., Yang H., Gere S., Hu Y., Buetow K.H., Lee M.P. Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer. Cancer Res. 2003, 63:655-657.
15. Duan W., Gao L., Druhan L.J., Zhu W.G., Morrison C., Otterson G.A., Villalona-Calero M.A. Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J. Natl. Cancer Inst. 2004, 96:1718-1721.
16. Shimada M., et al. High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers. Cancer Sci. 2009, 100:866-872.
17. Wang X.M., Yang L.Y., Guo L., Fan C., Wu F. P53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection. Cancer 2009, 115:4554-4563.
18. Cookson M.R., Lockhart P.J., McLendon C., O'Farrell C., Schlossmacher M., Farrer M.J. RING finger 1 mutations in Parkin produce altered localization of the protein. Hum. Mol. Genet. 2003, 12:2957-2965.
19. Lukas J., Gao D.Q., Keshmeshian M., Wen W.H., Tsao-Wei D., Rosenberg S., Press M.F. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res. 2001, 61:3212-3219.
20. Bartel F., Taubert H., Harris L.C. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2002, 2:9-15.
21. Sigalas I., Calvert A.H., Anderson J.J., Neal D.E., Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat. Med. 1996, 2:912-917.